Recs: 1 Surfaxin Approval Pop May Be Subdued Unless the uptick rule is reinstated the hedge funds and short funds appear to be able to control the price appreciation of promising biotechs. Today's example is IDEV. Today's press release is significant and the market bestows a 7 cent reward. Yawn. http://biz.yahoo.com/prnews/080822/nef006.html?.v= 68


